Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)

European Neuropsychopharmacology

Volumn 7, Issue 1, 1997, Pages 25-38

  Vollenweider, F X ^a   Leenders, K L ^b   Oye I ^c   Hell, D ^a   Angst, J ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

(S) and (R) ketamine enantiomeres; 18F fluorodeoxyglucose (FDG); cerebral glucose metabolism; frontal cortex; glutamate; model psychosis; N methyl D aspartate (NMDA) receptor; PET (positron emission tomography); schizophrenia; sigma receptor

Indexed keywords

GLUCOSE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; PLACEBO;

ADULT; ARTICLE; BRAIN METABOLISM; EGO PSYCHOLOGY; FEMALE; HALLUCINATION; HUMAN; HUMAN EXPERIMENT; MALE; MODEL; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA; STEREOISOMERISM;

ADULT; BRAIN CHEMISTRY; CEREBRAL CORTEX; FEMALE; FUNCTIONAL LATERALITY; GLUCOSE; HUMANS; KETAMINE; KINETICS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOSES, SUBSTANCE-INDUCED; STEREOISOMERISM; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030934458     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(96)00042-9     Document Type: Article

References (67)

1. Anis, N.A., Berry, S.C., Burton, N.R. and Lodge, D. (1983) The dissociative anesthetics, ketamine and phencyclidine selective reduce excitation of central mammalian neurons by N-methyl-D-aspartate. Br. J. Pharmacol. 79, 565-575.
2. Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie AMDP (1981) Das AMDP-System. Manual zur Dokumentation psychiatrischer Befunde. Springer-Verlag, Berlin.
3. Bowers, M.B. (1968) Pathogenesis of acute schizophrenic psychosis. Arch. Gen. Psychiatry 15, 240-248.
4. Bowers, M.B. and Freedman, D.X. (1966) 'Psychedelic' experiences in acute psychoses. Arch. Gen. Psychiatry 15, 240-248.
5. Buchsbaum, M.S., Nuechterlein, K.H., Haier, R.J., Wu, J., Sicotte, N., Hazlett, E., Asarnow, R., Potkin, S. and Guich, S. (1990) Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by positron emission tomography. Br. J. Psychiatry 156, 216-227.
6. Carlsson, M. and Carlsson, A. (1990) Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr. Bull. 16, 425-432.
7. Chapman, J. (1966) The early symptoms of schizophrenia. Br. J. Psychiatry 112, 225-251.
8. Cleghorn, J.M., Garnett, E.S., Nahmias, C., Firnau, G., Brown, G.M., Kaplan, R., Szechtman, H. and Szechtman, B. (1989) Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Res. 28, 119-133.
9. Collier, B.B. (1972) Ketamine and the conscious mind. Anaesthesia 27, 120-137.
10. Corssen, G., Miyasaka, M. and Domino, E.F. (1968) Changing concepts in pain control during surgery: dissociative anesthesia with CI-581. A progress report. Anesth. Analg. 47, 745-759.
11. de Wit, H., Metz, J., Wagner, N. and Cooper, M. (1990) Behavioral and subjective effects of ethanol: relationship to cerebral metabolism using PET. Alcohol Clin. Exp. Res. 14, 482-489.
12. de Wit, H., Metz, J. and Cooper, M. (1991) Effects of ethanol, diazepam and amphetamines on cerebral metabolic rate: PET studies using FDG. NIDA Res. Monogr. 105, 61-67.
13. Deakin, J.F.W., Slater, P., Simpson, M.D.C., Gilchrist, A.C., Skan, W.J., Royston, M.C., Reynolds, G.P. and Cross, A.J. (1989) Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 52, 1781-1786.
14. Debonnel, G. (1993) Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. J. Psychiatry Neurosci. 18, 157-172.
15. Dittrich, A. (1985) Ätiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände. Ferdinand Enke Verlag, Stuttgart.
16. Dittrich, A. (1994) Psychological aspects of altered states of consciousness of the LSD type: measurements of their basic dimensions and prediction of individuall differences. In: Pletscher, A. and Ladewig, D. (Eds.), 50 Years of LSD. Current Status and Perspectives of Hallucinogens. Parthenon Publishing, New York, pp. 101-118.
17. Dittrich, A., von Arx, S. and Staub, S. (1981) International study on altered states of consciousness (ISASC). Schweiz. Z. Psychol. und Anw. 40, 189-200.
18. Dittrich, A., von Arx, S. and Staub, S. (1985) International study on altered states of consciousness (ISASC). Summary of the results. Germ. J. Psychol. 9, 319-339.
19. Domino, E.F., Chodoff, P. and Corssen, S. (1965) Pharmacological effects of Cl-581, a new dissociative anesthetic in man. Clin. Pharmacol. Ther. 6, 279-291.
20. Ebmeier, K.P., Blackwood, D.H.R., Murray, C., Souza, V., Walker, M., Doughall, N., Moffoot, A.P.R., O'Carroll, R.E. and Goodwin, G.M. (1993) Single-photon emission computed tomography with 99 mTc-Exametazime in unmedicated schizophrenic patients. Biol. Psychiatry 33, 487-495.
21. Fahrenberg, J., Hampel, R. and Selg, H. (1984) Das Freiburger Persönlichkeitsinventar FPI. Hogrefe, Göttingen.
22. Feng, N., Vollenweider, F.X., Minder, E.I., Rentsch, K., Grampp, T. and Vonderschmitt, D.J. (1995) Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples. Ther. Drug Monit. 17, 95-100.
23. Freedman, B. and Chapman, L.J. (1973) Early subjective experiences in schizophrenic episodes. J. Abnorm. Psychol. 82, 46-54.
24. Friston, K.J., Passingham, R.E., Nutt, J.G., Heather, J.D., Sawle, G.V. and Frackowiak, R.S. (1989) Localisation in PET images: direct fitting of the intercommissural (AC-PC) line. J. Cereb. Blood Flow Metab. 9, 690-695.
25. Fristen, K.J., Frith, C.D., Liddle, P.F. and Frackowiak, R.S. (1991) Plastic transformation of PET images. J. Comput. Assist. Tomogr. 15, 634-639.
26. Ghoneim, M.M., Hinrichs, J.V., Mewaldt, S.P. and Petersen, R.C. (1985) Ketamine: behavioral effects of subanesthetic doses. J. Clin. Psychopharmacol. 5, 70-77.
27. Gouzoulis, E., Hermle, L. and Sass, H. (1994) Psychedelische Erlebnisse zu Beginn produktiver Episoden endogener Psychosen. Nervenarzt. 65, 198-201.
28. 3H]deoxy-D-glucose receptor binding technique. Proc. Natl. Acad. Sci. USA 79, 3067-3070.
29. Hansen, G., Jensen, S.B., Chandresh, L. and Hilden, T. (1989) The psychotropic effect of ketamine. J. Psychoactive Drugs 20, 419-425.
30. Hermle, L., Spitzer, M., Borchardt, D. and Gouzoulis, E. (1992) Beziehungen der Modell-bzw. Drogenpsychosen zu schizophrenen Erkrankungen. Fortschr. Neurol. Psychiat. 60, 383-392.
31. Ishimaru, M., Kurumaji, A. and Toru, M. (1994) Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol. Psychiatry 35, 84-95.
32. Janke, W. and Debus, G. (1978) Die Eigenschaftswörterliste (EWL-K)-Ein Verfahren zur Erfassung der Befindlichkeit. Hogrefe, Göttingen.
33. Kaplan, R.D., Szechtman, H., Franco, S., Szechtman, B., Nahmias, C., Garnett, E.S., List, S. and Cleghorn, J.M. (1993) Three clinical syndromes of schizophrenia in untreated subjects: relation to glucose activity measured by positron emission tomography (PET). Schizophr. Res. 11, 47-54.
34. Kim, J.S., Kornhuber, H.H., Schmid-Burke, W. and Holzmüller, B. (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20, 379-382.
35. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patiens. J. Neuronal Transm. 77, 231-236.
36. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.F., Delaney, R., Bremner, J.D., Heiniger, R., Bowers, M.B. and Charney, D.S. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch. Gen. Psychiatry 51, 199-214.
37. Lahti, A.C., Holcomb, H.H., Medoff, D.R. and Tamminga, C.A. (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport 6, 869-872.
38. Liddle, P.F., Friston, K.J., Frith, C.D., Hirsch, S.R. and Frackowiak, R.S.J. (1992) Patterns of cerebral blood flow in schizophrenia. Br. J. Psychiatry 160, 179-186.
39. London, E.D., Dam, M. and Weissman, A.D. (1988) Different patterns of cerebral glucose utilization produced by phencyclidine and D-N-allylnormetazocinel. In: Domino, E.F. and Kamenka, J.M. (Eds.), Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Michigan, pp. 297-326.
40. Luby, E.D., Cohen, B.D., Rosenbaum, G., Gottlieb, J.S. and Kelley, R. (1959) Study of a new schizophrenomimetic drug, Sernyl. Arch. Neurol. Psychiatry 81, 363-369.
41. Mathisen, L.C., Skjelbred, P., Skoglund, L.A. and Øye, I. (1995) Effect of ketamine, and NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 2694, 1-6.
42. McCabe, M.S., Fowler, R.C., Cadoret, R.J. and Winokur, G. (1972) Symptom differences in schizophrenia with good and poor progosis. Am. J. Psychiatry 128, 1239-1243.
43. Meltzer, H.Y., Fessler, R.G., Simonovic, M. and Fang, V.S. (1978) Stimulation of rat prolactin secretion by indolealkylamine hallucinogens. Psychopharmacology 56, 255-259.
44. Meltzer, H.Y., Sturgeon, R.D., Simonovic, M. and Fessler, R.G. (1981) Phencyclidine as an indirect dopamine agonist. In: Domino, E.F. (Ed.), PCP (Phencyclidine): Historical and Current Perspectives. NPP Books, Ann Arbor, pp. 207-242.
45. Nelson, S.R., Howard, R.B., Cross, R.S. and Samson, F. (1980) Ketamine-induced changes in regional glucose utilisation in the rat brain. Anesthesiology 52, 330-334.
46. Øye, I., Hustveit, O., Maurset, A., Ratti Moberg, E., Paulsen, O. and Skoglund, L.A. (1991) The chiral forms of ketamine as probes for NMDA-receptor function in humans. In: Kameyama, T., Nabeshima, T. and Domino, E.F. (Eds.), NMDA Receptor Related Agents: Biochemistry, Pharmacology and Behavior. NPP Books, Ann Arbor, pp. 381-389.
47. Øye, I., Paulsen, O. and Maurset, A. (1992) Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 260, 1209-1213.
48. Parellada, E., Catafau, A.M., Bernardo, M., Lomeña, F., González-Monclús, E. and Setoain, J. (1994) Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: a resting and activation SPECT study. Psychiatry Res. Neuroimag. 55, 131-139.
49. Piercey, M.F., Hoffmann, W.E. and Kaczkofsky, P. (1988) Functional evidence for PCP-like effects of the anti-stroke candidate MK-801. Psychopharmacology (Berlin) 96, 561-562.
50. Piercey, M.F. and Ray, C.A. (1988) Dramatic limbic and cortical effects mediated by high affinity PCP receptors. Life Sci. 43, 379-385.
51. Rhodes, C.G., Wise, R.J., Gibbs, J.M., Frackowiak, R.S., Hatazawa, J., Palmer, A.j., Thomas, D.G. and Jones, T. (1983) In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann. Neurol. 14, 614-626.
52. Scharfetter, C. (1981) Ego-psychopathology: the concept and its empirical evaluation. Psychol. Med. 11, 273-280.
53. Scharfetter, C. (1987) Paranoid-halluzinatorische Zustandsbilder bei drogeninduzierten Psychosen. In: Olbrich, H.M. (Ed.), Halluzination und Wahn. Springer-Verlag, Berlin, pp. 42-51.
54. Scharfetter, C. (1990a) EPP (Ego-Psychopathology). Psychiatric University Hospital Zürich, Research Department, Zürich.
55. Scharfetter, C. (1990b) Schizophrene Menschen. Psychologische Verlags Union, Urban and Schwarzenberg, Munich.
56. Scharfetter, C. (1995) The self-experience of schizophrenics. Empirical studies of the ego/self in schizophrenia, borderline disorders and depression. Psychiatric University Hospital of Zürich, University Press (ISBN 3-9520832-1-6), Zürich.
57. Sherman, A.D., Hegwood, T.S., Baruah, S. and Waziri, R. (1991) Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biol. Psychiatry 30, 1191-1198.
58. Simpson, M.D.C., Slater, P., Royston, M.C. and Deakin, J.F.W. (1992) Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Schizophr. Res. 6, 41-48.
59. Talairach, J. and Tournoux, P. (1988) Co-planar stereotaxic atlas of the human brain. Thieme, Stuttgart.
60. Tamminga, C.A., Tanimoto, K., Kuo, S., Chase, T.N., Contreras, P.C., Rice, K.C., Jackson, A.E. and O'Donohue, T.L. (1987) PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agent. Synapse 1, 497-504.
61. Volkow, N.D., Brodie, J.D., Wolf, A.P., Angrist, B., Russell, J. and Cancro, R. (1986) Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration. Neurosurg. Psychiatry 49, 1199-1202.
62. Vollenweider, F.X. (1992) Die Anwendung von Psychotomimetika in der Schizophrenieforschung unter besonderer Berücksichtigung der Ketamin/PCP-Modell-Psychose. SUCHT 38, 389-409.
63. Vollenweider, F.X., Leenders, K.L., Scharfetter, C., Maguire, P., Stadelmann, O. and Angst, J. (1995) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology (submitted for publication).
64. 18F]fluorodeoxyglocose (FDG). Eur. Neuropsychopharmacol. (in press).
65. Weber, A.C. and Scharfetter, C. (1984) The syndrome concept: history and statistical operationalizations. Psychol. Med. 14, 315-325.
66. Weissman, A.D., Su, T.P., Hedreen, J.C. and London, E.D. (1988) Sigma receptor in post-mortem human brains. J. Pharmacol. Exp. Ther. 247, 29-33.
67. Zeilhofer, H.U., Swandulla, D., Geisslinger, G. and Brune, K. (1992) Differential effects of ketamine enantiomeres on NMDA receptor currents in cultured neurons. Eur. J. Pharmacol. 213, 155-158.